Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan and Renal Handling in ADPKD (TOPO)
NCT02527863Phase 2Completed
- Sponsor
- Regionshospitalet Holstebro
- Start
- Feb 2015
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tolvaptan in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Regionshospitalet Holstebro. Primary endpoint: Free Water Clearance. Started Feb 2015; status: completed.
02
Drugs
tolvaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT02527863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02527863.